Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Immune Cell Profiles in Patients Treated with Lenalidomide and Alternate Day Prednisolone Maintenance Post Upfront ASCT for Multiple Myeloma (LEOPARD Trial)

Anna Kalff, MBBS (Hons) FRACP FRCPA, Sam Norton, PhD, Tiffany Khong, BSc, PhD, Malarmathy Ramachandran, Mary H. Young, PhD, William Pierceall, Anjan Thakurta, Udo Oppermann, PhD, Manman Guo, John Reynolds, PhD, Andrew Spencer

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-141746

Published: 2020

Journal Articles

Phase 1, First-in-Human Study of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-136375

Published: 2020

Journal Articles

Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study

Georgia J McCaughan, MBBS, Steven Tran, BEng MBiomedE, Simon Durrant, MBBS FRCP FRCPath, Simon J Harrison, MBBS MRCP (UK) PhDFRCPath (UK) FRACP, James Morton, MBBS BSci (MD FRACP FRCPA GAICD, Noemi Horvath, MB ChB FRACP FRCPA, Andrew Spencer, Ian H. Kerridge, FRACP FRCPA MPhil BA, Jeremy An Ke Er, MBBS, Luani Barge, MChD, BSc, Adam Bryant, MBBS (Hon) PhDFRACP FRCPA, Robin J Filshie, MBChB, PhD FRACP, FRCPA, Emily Choong, BSc MBBS, Hock Choong Lai, MBBS, FRACP, FRCPA, Campbell Tiley, MBBS FRACP, Anthony K Mills, MBBS FRACP FRCPA, Andrew Butler, MB ChB(Edin), MRCP, MRCPath, John Moore, MB.BS, MD FRACP, FRCPA, Mark Hertzberg, MBBS PhDFRACP FRCPA, Glen A Kennedy, MBBS FRACP FRCPA, P. Joy Ho, MB.BS. (Hons), D.Phil (Oxon), FRACP, FRCPA, FFSc(RCPA), M Hasib Sidiqi, MBBS, John Bashford, BSc MBBS FRACP FRCPA, David Routledge, BSc (Hons) MBChB MSc PGCert MRCP FRCPath UK RACP, Kerry Taylor, MBBS(Hons) FRACP FRCPA, Cindy H. Lee, MBBS FRACP FRCPA, Anna Kalff, MBBS (Hons) FRACP FRCPA, Wei Xia, MBBS PhD, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-138991

Published: 2020

Journal Articles

A Longitudinal Evaluation of Euroflow and Combined Quantitative Immunoprecipitation (QIP) and Free Light Chain (FLC) Mass Spectometry (MS) in Functional High Risk Multiple Myeloma

Andrew Spencer, DM, Tiffany Khong, BSc, PhD, Flora Yuen, BBiomedSc, Hannah Victoria Giles, FRCPath, MRCP, Malgorzata Gorniak, BSc, Hang Quach, MBBS, FRACP, FRCPA, MD, Noemi Horvath, MBBS FRACP FRCPA, Ian H. Kerridge, FRACP,FRCPA,MPhil,BA, Edwin Sze-Hung Lee, MD FRACP, FRCP, FRCPA, FRCPath, Krystal Bergin, Shreerang Sridesai, MBBS, FRACP, FRCPA, Anna Kalff, MBBS, John Reynolds, PhD

Blood (2019) 134 (Supplement_1): 3090.

https://doi.org/10.1182/blood-2019-129760

Published: 2019

Journal Articles

Identification of Novel Immune Cell Populations in Lenalidomide Refractory Relapsed Multiple Myeloma Patients Treated with Pomalidomide and Low Dose Dexamethasone

Anna Kalff, MBBS, Tiffany Khong, BSc, PhD, Malarmathy Ramachandran, Sam Norton, PhD, Andrew Mitchell, PhD, John Reynolds, PhD, Hang Quach, MBBS, FRACP, FRCPA, MD, P Joy Ho, MBBS(Syd) DPhil(Oxon) FRACP FRCPA FFSc(RCPA), Noemi Horvath, MBBS FRACP FRCPA, Peter Mollee, MBBS, MMSc, FRACP, FRCPA, Nola Kennedy, Roslyn Kemp, Andrew Spencer, DM

Blood (2019) 134 (Supplement_1): 3186.

https://doi.org/10.1182/blood-2019-130154

Published: 2019

Journal Articles

A Sequential Cohort Study Comparing Kappamab Alone to Kappamab, Lenalidomide and Low Dose Dexamethasone in Kappa-Restricted Relapsed Refractory Multiple Myeloma (AMaRC 01-16)

Anna Kalff, MBBS, Jake Shortt, MBBS FRACP FRCPA PhD, Flora Yuen, BBiomedSc, John Reynolds, PhD, Hang Quach, MBBS, FRACP, FRCPA, MD, Craig Thomas Wallington-Beddoe, BSc,MBBS,PhDFRACP,FRCPA, Patricia Walker, MBBS, BMedSci, FRACP, FRCPA, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Rosanne Dunn, PhD, Andrew Spencer, DM

Blood (2019) 134 (Supplement_1): 3144.

https://doi.org/10.1182/blood-2019-130084

Published: 2019

Journal Articles

Phase 2 Trial of the Combination of Ixazomib, Thalidomide and Dexamethasone (ITD) in Relapsed/Refractory Myeloma: Planned Preliminary Analysis

Krystal Bergin, Flora Yuen, BBiomedSc, Craig Thomas Wallington-Beddoe, BSc, MBBS, PhD FRACP, FRCPA, Anna Kalff, MBBS, Shreerang Sirdesai, MBBS, FRACP, FRCPA, John Reynolds, PhD, Andrew Spencer, MBBS, MD FRACP, FRCPA

Blood (2018) 132 (Supplement 1): 3265.

https://doi.org/10.1182/blood-2018-99-118172

Published: 2018

Journal Articles

Pomalidomide Alone or in Combination with Low Dose Dexamethasone As Maintenance Following Induction with Pomalidomide and Low Dose Dexamethasone in Relapsed and Refractory Myeloma (ALLG MM14)

Anna Kalff, MBBS, Nola Kennedy, John Reynolds, PhD, Hang Quach, MDFRACP,FRCPA,MBBS, Phoebe Joy Ho, MBBS, Noemi Horvath, MBBS FRACP FRCPA, Peter Mollee, FRACP, FRCPA, MBBS, MMSc, James M. D'Rozario, MBBS, FRACP, FRCPA, Kerry Taylor, FRACP,FRCPA,MBBS, Jane Estell, FRACP, Andrew Spencer, MBBS, MD FRACP, FRCPA

Blood (2018) 132 (Supplement 1): 1986.

https://doi.org/10.1182/blood-2018-99-118231

Published: 2018

Journal Articles

Preliminary Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) MM17 Trial: Response Adaptive Salvage Treatment with Carfilzomib-Thalidomide-Dexamethasone (KTd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy

Andrew Spencer, MBBS, FRACP, FRCPA, DM, Hang Quach, MD FRACP, FRCPA, MBBS, Noemi Horvath, MBBS FRACP FRCPA, Ian H. Kerridge, FRACP, FRCPA, MPhil, BA, Flora Yuen, BBiomedSc, Edwin Sze-Hung Lee, MD FRACP, FRCP, FRCPA, FRCPath, Edward S. Morris, BMBS, DM, Anna Kalff, MBBS, Krystal Bergin, Shreerang Sirdesai, MBBS, FRACP, FRCPA, Malgorzata Gorniak, BSc, Sridurga Mithraprabhu, PhD MSc, Tiffany Khong, BSc, PhD, John Reynolds, PhD

Blood (2018) 132 (Supplement 1): 3279.

https://doi.org/10.1182/blood-2018-99-113982

Published: 2018

Journal Articles

Identification of Acetylation, Immune Cell Alterations and Gene Signature As Dynamic Biomarkers of Response to Panobinostat Treatment in Multiple Myeloma Patients

Sridurga Mithraprabhu, PhD MSc, Ioanna Savvidou, MD, Malarmathy Ramachandran, Anna Kalff, MBBS, Tiffany T. Khong, BSc,PhD, Kate Reed, John Reynolds, PhD, Andrew Spencer, MD

Blood (2017) 130 (Supplement 1): 1823.

https://doi.org/10.1182/blood.V130.Suppl_1.1823.1823

Published: 2017

Journal Articles

High Risk Multiple Myeloma: Better Outcomes with Upfront Tandem Autologous- Non-Myelo Ablative Allogeneic Stem Cell Transplantation Compared to Upfront Autologous Stem Cell Transplantation

Anish Puliyayil Nair, MD DM, FRACP, Cindy Lee, FRACP, FRCPA, Anna Kalff, MBBS, FRACP, FRCPA, Patricia A. Walker, MBBS, FRACP, FRCPA, Krystal Bergin, Jay Hocking, MD PhDstudent, Sue Morgan, FRACP, FRCPA, MBBS, Daniela Klarica, RN, Jenny Muirhead, Andrew Spencer, Oi Lin Lee, Noemi Horvath, MB, ChB, FRACP, FRCPA

Blood (2016) 128 (22): 4684.

https://doi.org/10.1182/blood.V128.22.4684.4684

Published: 2016

Journal Articles

A 2-Stage Phase II Study of Panobinostat Consolidation in Multiple Myeloma (MM) Patients with < CR Following Single High-Dose Chemotherapy (HDT) Conditioned Autologous Stem Cell Transplantation (ASCT) As Part of First Line Therapy

Anna Kalff, MBBS, FRACP, FRCPA, Sridurga Mithraprabhu, PhD, Tiffany T. Khong, PhD, Malarmathy Ramachandran, Kate Reed, Hang Quach, MBBS (Hons), FRACP, FRCPA, MD, Patricia A. Walker, MBBS, FRACP, FRCPA, Krystal Bergin, Andrew Spencer

Blood (2016) 128 (22): 4515.

https://doi.org/10.1182/blood.V128.22.4515.4515

Published: 2016

Journal Articles

Roar: A Phase Ib Trial of Oral Azacitidine (CC-486) in Combination with Lenalidomide and Dexamethasone (Rd) for Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma Who Have Failed a Prior Lenalidomide-Containing Regimen

Anna Kalff, MBBS, FRACP, FRCPA, Kate Reed, Tiffany T. Khong, PhD, Sridurga Mithraprabhu, PhD, Malarmathy Ramachandran, John Reynolds, Krystal Bergin, Anjan Thakurta, PhD, Maria Wang, PhD, Andrew Spencer, Roberto Guzman, Suzana Cuoto, Yan Ren, MD

Blood (2016) 128 (22): 2121.

https://doi.org/10.1182/blood.V128.22.2121.2121

Published: 2016

Journal Articles

Mutational Characterisation and Tracking Disease Progression Using Circulating Cell-Free Tumor DNA in Multiple Myeloma Patients

Sridurga Mithraprabhu, PhD, Tiffany Khong, BSc, PhD, Malarmathy Ramachandran, Annie W.S. Chow, Daniela Klarica, RN, Laura Mai, Stephanie Walsh, David Broemeling, Andre Marziali, Matthew Wiggin, Jay Hocking, MD PhDstudent, Anna Kalff, MBBS, FRACP, FRCPA, Brian G.M. Durie, MD, Andrew Spencer

Blood (2016) 128 (22): 3280.

https://doi.org/10.1182/blood.V128.22.3280.3280

Published: 2016

Journal Articles

Autologous Stem Cell Transplantation (ASCT) Followed By Outpatient-Based Non-Myeloblative Allogeneic (NMA) Stem Cell Transplantation (Tandem Auto-Allo) for Biologically Adverse Multiple Myeloma (MM). a Single Centre Experience from Australia

Anish Puliyayil Nair, MD DM, Patricia A. Walker, MBBS, FRACP, FRCPA, Anna Kalff, MBBS, FRACP, FRCPA, Krystal Bergin, MBBS, Sharon Avery, MBBS (Hons), FRACP, FRCPA, David J. Curtis, MD, PhD, Sushrut S. Patil, FRACP, FRCPA, Jenny Muirhead, Tongted Phomoonna, Daniela Klarica, RN, Andrew Spencer

Blood (2015) 126 (23): 2030.

https://doi.org/10.1182/blood.V126.23.2030.2030

Published: 2015

Journal Articles

Leopard: A Phase II Study of Maintenance Lenalidomide and Prednisolone Post Autologous Stem Cell Transplantation (ASCT) for Myeloma, Incorporating Minimal Residual Disease Assessments

Anna Kalff, MBBS, FRACP, FRCPA, Nola Kennedy, Patricia A. Walker, MBBS, FRACP, FRCPA, Tiffany T. Khong, BSc, PhD, Anthony Schwarer, MD, Andrew W. Roberts, MBBS, PhD, Philip Campbell, MBBS, FRACP, FRCPA, Robin Filshie, PhD FRACP, Angela Smiley, Malgorzata Gorniak, Marion Black, Nicole Jenkins, Geoffrey Raines, Andrew Spencer, MBBS FRACP FRCPA MD

Blood (2014) 124 (21): 2103.

https://doi.org/10.1182/blood.V124.21.2103.2103

Published: 2014

Journal Articles

Thrombin Generation and Venous Thromboembolism Among Multiple Myeloma Patients Receiving Lenalidomide and Prednisolone Maintenance Following Autologous Stem Cell Transplantation (ASCT)

Huyen Tran, MBBS, MSc, James David McFadyen, MD, Anna Kalff, MBBS, Andrew Spencer, MD

Blood (2014) 124 (21): 5072.

https://doi.org/10.1182/blood.V124.21.5072.5072

Published: 2014

Journal Articles

Leopard: A Phase II Study Of Post Autologous Stem Cell Transplantation (ASCT) Maintenance Lenalidomide and Prednisolone For Myeloma (MM), Incorporating Minimal Residual Disease (MRD) Assessments

Anna Kalff, MBBS, FRACP, FRCPA, Nola Kennedy, Patricia A. Walker, MBBS, FRACP, FRCPA, Marion Black, Odette Youdell, Malgorzata Gorniak, Tiffany T. Khong, BSc, PhD, Lona Estifo, Angela Smiley, Anthony P. Schwarer, MD, Andrew W. Roberts, MBBS, PhD, Philip Campbell, MBBS, FRACP, FRCPA, Robin Flishie, Andrew Spencer, MD

Blood (2013) 122 (21): 3223.

https://doi.org/10.1182/blood.V122.21.3223.3223

Published: 2013

Journal Articles

Outpatient Non-Myeloablative Allogeneic Stem Cell Transplantation For Myeloma Is Feasible, Efficacious and Associated With Low Transplant-Related Morbidity and Mortality

Philip Campbell, MBBS, FRACP, FRCPA, Patricia A. Walker, MBBS, FRACP, FRCPA, Sharon Avery, MBBS, Sushrut S. Patil, FRACP, FRCPA, David J. Curtis, M.D., Ph.D., Anthony P. Schwarer, MD, Andrew H Wei, MBBS, PhD, Anna Kalff, MBBS, FRACP, FRCPA, Jenny Muirhead, Andrew Spencer, MD

Blood (2013) 122 (21): 2128.

https://doi.org/10.1182/blood.V122.21.2128.2128

Published: 2013

Journal Articles

Incidence and Kinetics Of Full Donor Chimerism and The Impact Of Minimal Residual Disease Status Following Outpatient Non-Myeloablative Allogeneic Stem Cell Transplantation For Myeloma

Philip Campbell, MBBS, FRACP, FRCPA, Tongted Das, David Kipp, Patricia A. Walker, MBBS, FRACP, FRCPA, Jenny Muirhead, Sharon Avery, MBBS, Sushrut S. Patil, FRACP, FRCPA, David J. Curtis, M.D., Ph.D., Anthony P. Schwarer, MD, Anna Kalff, MBBS, FRACP, FRCPA, Andrew Spencer, MD

Blood (2013) 122 (21): 2129.

https://doi.org/10.1182/blood.V122.21.2129.2129

Published: 2013

NARROW

Immune Cell Profiles in Patients Treated with Lenalidomide and Alternate Day Prednisolone Maintenance Post Upfront ASCT for Multiple Myeloma (LEOPARD Trial)

Phase 1, First-in-Human Study of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Multiple Myeloma

Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study

A Longitudinal Evaluation of Euroflow and Combined Quantitative Immunoprecipitation (QIP) and Free Light Chain (FLC) Mass Spectometry (MS) in Functional High Risk Multiple Myeloma

Identification of Novel Immune Cell Populations in Lenalidomide Refractory Relapsed Multiple Myeloma Patients Treated with Pomalidomide and Low Dose Dexamethasone

A Sequential Cohort Study Comparing Kappamab Alone to Kappamab, Lenalidomide and Low Dose Dexamethasone in Kappa-Restricted Relapsed Refractory Multiple Myeloma (AMaRC 01-16)

Phase 2 Trial of the Combination of Ixazomib, Thalidomide and Dexamethasone (ITD) in Relapsed/Refractory Myeloma: Planned Preliminary Analysis

Pomalidomide Alone or in Combination with Low Dose Dexamethasone As Maintenance Following Induction with Pomalidomide and Low Dose Dexamethasone in Relapsed and Refractory Myeloma (ALLG MM14)

Preliminary Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) MM17 Trial: Response Adaptive Salvage Treatment with Carfilzomib-Thalidomide-Dexamethasone (KTd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy

Identification of Acetylation, Immune Cell Alterations and Gene Signature As Dynamic Biomarkers of Response to Panobinostat Treatment in Multiple Myeloma Patients

High Risk Multiple Myeloma: Better Outcomes with Upfront Tandem Autologous- Non-Myelo Ablative Allogeneic Stem Cell Transplantation Compared to Upfront Autologous Stem Cell Transplantation

A 2-Stage Phase II Study of Panobinostat Consolidation in Multiple Myeloma (MM) Patients with < CR Following Single High-Dose Chemotherapy (HDT) Conditioned Autologous Stem Cell Transplantation (ASCT) As Part of First Line Therapy

Roar: A Phase Ib Trial of Oral Azacitidine (CC-486) in Combination with Lenalidomide and Dexamethasone (Rd) for Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma Who Have Failed a Prior Lenalidomide-Containing Regimen

Mutational Characterisation and Tracking Disease Progression Using Circulating Cell-Free Tumor DNA in Multiple Myeloma Patients

Autologous Stem Cell Transplantation (ASCT) Followed By Outpatient-Based Non-Myeloblative Allogeneic (NMA) Stem Cell Transplantation (Tandem Auto-Allo) for Biologically Adverse Multiple Myeloma (MM). a Single Centre Experience from Australia

Leopard: A Phase II Study of Maintenance Lenalidomide and Prednisolone Post Autologous Stem Cell Transplantation (ASCT) for Myeloma, Incorporating Minimal Residual Disease Assessments

Thrombin Generation and Venous Thromboembolism Among Multiple Myeloma Patients Receiving Lenalidomide and Prednisolone Maintenance Following Autologous Stem Cell Transplantation (ASCT)

Leopard: A Phase II Study Of Post Autologous Stem Cell Transplantation (ASCT) Maintenance Lenalidomide and Prednisolone For Myeloma (MM), Incorporating Minimal Residual Disease (MRD) Assessments

Outpatient Non-Myeloablative Allogeneic Stem Cell Transplantation For Myeloma Is Feasible, Efficacious and Associated With Low Transplant-Related Morbidity and Mortality

Incidence and Kinetics Of Full Donor Chimerism and The Impact Of Minimal Residual Disease Status Following Outpatient Non-Myeloablative Allogeneic Stem Cell Transplantation For Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only